0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

THE DISADVANTAGES INCIDENT TO THE ADMADMINISTRATION OF SALVARSAN

DOUGLASS W. ONTGOMERY, M.M.D.
JAMA. 1911;LVII(21):1661-1666. doi:10.1001/jama.1911.04260110161004.
Text Size: A A A
Published online

Salvarsan in its present form can never become a popular remedy. Paul Ehrlich, however, is so ingenious that any day he may invent a modification that will be more easily administered, and will be even less toxic.

There are three determinations of salvarsan that are of fundamental imptance; its poisonous action on the Spirochœta pallida; its selective action on epithelial tisue; and its selective action on the tissue of nerves. Its stimulating action on epithelial tissue is shown in the marvelous way mucous patches and leutic ulcers epidermize under its influence. Its selective action on nerve tissue, however, is what immediately interests us in this paper.

On the introduction of salvarsan, the attention of observers was fixed on the optic nerve, as it was feared that salvarsan might, like atoxyl, cause amaurosis. But experience accumulated, and as no reports of dissagreable ocular symptomss were at first recorded it wass hoped

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();